Humacyte Statistics
Total Valuation
Humacyte has a market cap or net worth of $283.49 million. The enterprise value is $330.21 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, before market open.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Humacyte has 158.37 million shares outstanding. The number of shares has increased by 22.81% in one year.
| Current Share Class | 158.37M |
| Shares Outstanding | 158.37M |
| Shares Change (YoY) | +22.81% |
| Shares Change (QoQ) | +17.85% |
| Owned by Insiders (%) | 7.25% |
| Owned by Institutions (%) | 37.11% |
| Float | 125.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 249.51 |
| Forward PS | 19.98 |
| PB Ratio | 59.03 |
| P/TBV Ratio | 70.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 403.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.45, with a Debt / Equity ratio of 20.72.
| Current Ratio | 2.45 |
| Quick Ratio | 1.82 |
| Debt / Equity | 20.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.60 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -50.18% |
| Return on Invested Capital (ROIC) | -100.22% |
| Return on Capital Employed (ROCE) | -94.50% |
| Revenue Per Employee | $3,718 |
| Profits Per Employee | -$266,945 |
| Employee Count | 220 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.77% in the last 52 weeks. The beta is 1.87, so Humacyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.87 |
| 52-Week Price Change | -65.77% |
| 50-Day Moving Average | 1.95 |
| 200-Day Moving Average | 2.77 |
| Relative Strength Index (RSI) | 56.85 |
| Average Volume (20 Days) | 3,110,657 |
Short Selling Information
The latest short interest is 33.60 million, so 21.22% of the outstanding shares have been sold short.
| Short Interest | 33.60M |
| Short Previous Month | 34.25M |
| Short % of Shares Out | 21.22% |
| Short % of Float | 26.84% |
| Short Ratio (days to cover) | 5.85 |
Income Statement
In the last 12 months, Humacyte had revenue of $818,000 and -$58.73 million in losses. Loss per share was -$0.44.
| Revenue | 818,000 |
| Gross Profit | -80.55M |
| Operating Income | -111.23M |
| Pretax Income | -105.70M |
| Net Income | -58.73M |
| EBITDA | -103.92M |
| EBIT | -111.23M |
| Loss Per Share | -$0.44 |
Full Income StatementBalance Sheet
The company has $38.03 million in cash and $83.96 million in debt, giving a net cash position of -$45.93 million or -$0.29 per share.
| Cash & Cash Equivalents | 38.03M |
| Total Debt | 83.96M |
| Net Cash | -45.93M |
| Net Cash Per Share | -$0.29 |
| Equity (Book Value) | 4.05M |
| Book Value Per Share | 0.03 |
| Working Capital | 30.65M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$104.50 million and capital expenditures -$1.79 million, giving a free cash flow of -$106.29 million.
| Operating Cash Flow | -104.50M |
| Capital Expenditures | -1.79M |
| Free Cash Flow | -106.29M |
| FCF Per Share | -$0.67 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -13,598.04% |
| Pretax Margin | -7,171.27% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Humacyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.81% |
| Shareholder Yield | -22.81% |
| Earnings Yield | -20.66% |
| FCF Yield | -37.39% |
Analyst Forecast
The average price target for Humacyte is $10.88, which is 507.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.88 |
| Price Target Difference | 507.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Humacyte has an Altman Z-Score of -6.82. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.82 |
| Piotroski F-Score | n/a |
